AlphaMeld® is an AI-based, universal signal detection system built on the premise that every innovation begins with a core discovery or invention that gathers momentum. Powered by artificial intelligence and machine learning the platform accelerates innovation by identifying alpha signals of innovation for targets, drugs, and healthcare products and technologies. Primed with data sets that have been curated and connected for over a decade, the platform generates testable hypotheses based on an ideal mode of pharmacotherapy (antibody, protein replacement, siRNA, mRNA, small molecule, cell and gene therapy, and gene-editing modalities), disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies while factoring in medical, scientific, strategic, and commercial considerations. Operating in real-time, AlphaMeld® shapes and drives healthcare innovation by ensuring that the most discrete signals are detected, amplified, and taken into account.
Generating the highest quality datasets is foundational to the results we acquire. We have spent over a decade curating and connecting data sets (internal and externally sourced, structured and unstructured) and continue to add new data points to ensure data reliability, validity, and relatability.